ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
基本信息
- 批准号:6287020
- 负责人:
- 金额:$ 30.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-12-01 至 2004-11-30
- 项目状态:已结题
- 来源:
- 关键词:apolipoprotein E atherosclerosis atherosclerotic plaque biological signal transduction cell proliferation colony stimulating factor disease /disorder model gene expression genetic regulatory element guanine nucleotide binding protein immunocytochemistry laboratory mouse macrophage mitogen activated protein kinase molecular pathology protein localization protein structure function radiotracer site directed mutagenesis stromelysin tissue /cell culture transcription factor urokinase vascular smooth muscle
项目摘要
Macrophage(MO)-colony stimulating factor (M-CSF) importantly
contributes to the development of atherosclerotic lesions. We have found that
the absence of M-CSF in atherosclerosis-prone apolipoprotein (apo) E or
low-density lipoprotein receptor (LDLR)- deficient mice results in
substantially reduced atherosclerosis despite augmented hypercholesterolemia.
Our most recent studies provide compelling evidence in favor of a direct local
effect of M-CSF within the vessel wall. These advances, together with the
characterization of the M-CSF-mediated induction of urokinase plasminogen
activator (uPA) and matrix metalloproteinases (MMPs) cascade have prompted more
refined questions on the molecular mechanisms responsible for the full range of
M-CSF actions in the diseased vessel wall. In this proposal, we seek to extend
our research efforts to understand the role of M-CSF in the development and
disruption of arterial lesions by testing following three hypotheses: 1)
pleiotropic effects of M-CSF on intimal MO and SMC are modulated mainly through
the activation of nuclear factors downstream to the Ras-mediated cell signaling
pathways. One such factor is the transcription factor Ets-2 that promotes cell
proliferation and survival, 2) increased M-CSF activity in atherosclerotic
lesions contributes to the MO -mediated matrix remodeling by up regulating the
expression of uPA and MT3-MMP genes. This effect of M-CSF may play a role in
plaque disruption, and 3) M-CSF up regulates the MO-specific transcription of
uPA and MT3-MMP genes by activating a common set of trans-acting factors (such
as Ets family of transcription factors) that form ternary complexes with AP-l
and bind to cis-acting DNA elements present in the 5' regulatory region of
these genes. The specific aims are: 1) to investigate the effects of M-CSF on
the growth of arterial lesion-associated cells in vivo using mice lacking M-CSF
and/or apoE and to perform in vitro studies using cultured cells from
M-CSF-deficient mice to determine the mechanism(s) underlying the M-CSF
mediated proliferation and survival of MO and SMC, 2) to determine the effects
of M-CSF on the expression of uPA and MT3-MMP in cultured MO and to examine the
association of M-CSF regulated production of uPA and MT3-MMP to alterations in
the character of atherosclerotic lesions, and 3) to identify the cis-acting
elements in the uPA and MT3-MMP promoters that mediate the inductive effects of
M-CSF on the expression of these genes and to examine the signaling events
connecting M-CSF with the nuclear regulators of uPA and MT3-MMP. We believe our
studies will provide new and important information regarding the role of M-CSF
in the development and disruption of atherosclerotic and proliferative vascular
lesions and this information may prove useful in design of novel therapeutic
interventions for vascular diseases.
巨噬细胞集落刺激因子(M-CSF)
有助于动脉粥样硬化病变的发展。我们发现
易发生动脉粥样硬化的载脂蛋白(apo)E或M-CSF的缺乏
低密度脂蛋白受体(LDLR)缺陷小鼠导致
显著降低动脉粥样硬化,尽管增加高胆固醇血症。
我们最近的研究提供了令人信服的证据,支持直接的局部
M-CSF在血管壁内的作用。这些进步,加上
M-CSF介导的尿激酶纤溶酶原诱导的表征
激活剂(uPA)和基质金属蛋白酶(MMPs)级联反应促使更多
精细的问题的分子机制负责的全方位的
M-CSF在病变血管壁中的作用。在这一建议中,我们寻求扩大
我们的研究努力,以了解M-CSF在发展中的作用,
通过测试以下三个假设来破坏动脉病变:1)
M-CSF对内膜MO和SMC的多效性作用主要通过
Ras介导的细胞信号传导下游的核因子的激活
途径。一种这样的因子是转录因子Ets-2,其促进细胞增殖,
增殖和存活,2)增加的M-CSF活性在动脉粥样硬化
损伤通过上调细胞因子的表达,促进MO介导的基质重塑。
uPA和MT3-MMP基因的表达。M-CSF的这种作用可能在
斑块破坏,和3)M-CSF上调MO特异性转录
uPA和MT3-MMP基因通过激活一组共同的反式作用因子(如
作为转录因子的Ets家族)与AP-1形成三元复合物
并结合存在于5'调控区的顺式作用DNA元件,
这些基因。具体目的是:1)研究M-CSF对人肝癌细胞的作用,
使用缺乏M-CSF的小鼠体内动脉病变相关细胞的生长
和/或apoE,并使用来自
M-CSF缺陷小鼠,以确定M-CSF
介导的MO和SMC的增殖和存活,2)以确定
M-CSF对培养MO中uPA和MT3-MMP表达的影响,并检测其对MO的影响。
M-CSF调节的uPA和MT3-MMP的产生与
动脉粥样硬化病变的特征,以及3)确定顺式作用
uPA和MT3-MMP启动子中介导以下诱导效应的元件:
M-CSF对这些基因表达的影响,并检查信号事件
将M-CSF与uPA和MT3-MMP的核调节剂连接。我们相信我们的
研究将提供有关M-CSF作用的新的重要信息
在动脉粥样硬化和血管增生的发展和破坏中,
这些信息可能有助于设计新的治疗方法,
血管疾病的干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tripathi Byasmuni Rajavashisth其他文献
Tripathi Byasmuni Rajavashisth的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tripathi Byasmuni Rajavashisth', 18)}}的其他基金
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
- 批准号:
2609329 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
- 批准号:
6476934 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
- 批准号:
2229051 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
- 批准号:
6682346 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
- 批准号:
6625308 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
- 批准号:
2029081 - 财政年份:1994
- 资助金额:
$ 30.6万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
- 批准号:
10974007 - 财政年份:2023
- 资助金额:
$ 30.6万 - 项目类别:














{{item.name}}会员




